JP2019512528A - 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法 - Google Patents

抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法 Download PDF

Info

Publication number
JP2019512528A
JP2019512528A JP2018550327A JP2018550327A JP2019512528A JP 2019512528 A JP2019512528 A JP 2019512528A JP 2018550327 A JP2018550327 A JP 2018550327A JP 2018550327 A JP2018550327 A JP 2018550327A JP 2019512528 A JP2019512528 A JP 2019512528A
Authority
JP
Japan
Prior art keywords
disorder
hnk
ketamine
anxiety
hydroxynorketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018550327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512528A5 (https=
Inventor
アービング ワイナー
アービング ワイナー
カルロス ザラテ
カルロス ザラテ
ルイン モアデル
ルイン モアデル
トッド ゴウルド
トッド ゴウルド
パノス ザノス
パノス ザノス
クレイグ トーマス
クレイグ トーマス
パトリック モリス
パトリック モリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019512528A publication Critical patent/JP2019512528A/ja
Publication of JP2019512528A5 publication Critical patent/JP2019512528A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018550327A 2016-03-25 2017-03-27 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法 Pending JP2019512528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313317P 2016-03-25 2016-03-25
US62/313,317 2016-03-25
PCT/US2017/024238 WO2017165877A1 (en) 2016-03-25 2017-03-27 Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders

Publications (2)

Publication Number Publication Date
JP2019512528A true JP2019512528A (ja) 2019-05-16
JP2019512528A5 JP2019512528A5 (https=) 2020-05-07

Family

ID=58530652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018550327A Pending JP2019512528A (ja) 2016-03-25 2017-03-27 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法

Country Status (7)

Country Link
US (1) US20190083420A1 (https=)
EP (1) EP3432869A1 (https=)
JP (1) JP2019512528A (https=)
CN (1) CN109475514A (https=)
AU (1) AU2017238858A1 (https=)
CA (1) CA3019012A1 (https=)
WO (1) WO2017165877A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
AU2017238859B2 (en) 2016-03-25 2021-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
EP3442940A1 (en) * 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
ES2991544T3 (es) * 2016-11-30 2024-12-04 Wolfson Philip E Ketamina para el tratamiento de síntomas relacionados con la menstruación
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CN110343050B (zh) * 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
CN110540510B (zh) * 2019-05-24 2020-08-07 北京大学深圳研究生院 一种长效化合物的制备方法
KR20220097405A (ko) * 2019-11-05 2022-07-07 클라에스 툴린 포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘
CN113125586B (zh) * 2019-12-31 2022-05-24 成都百裕制药股份有限公司 一种1-[2-(2，4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法
CN112521357B (zh) * 2020-08-31 2021-10-08 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物及其制备方法
US12486242B2 (en) 2020-08-31 2025-12-02 Shenzhen Ruijian Biotechnology Co., Ltd. Long-acting low-addiction HNK derivative and preparation method therefor
CN112516130B (zh) * 2020-08-31 2022-01-04 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
WO2022041171A1 (zh) 2020-08-31 2022-03-03 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物及其制备方法
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
CN114947839B (zh) * 2022-05-27 2025-12-02 华东师范大学 大脑调控的训练方法、装置及电子设备
CN120736994B (zh) * 2025-01-26 2025-11-18 上海东西智荟生物医药有限公司 氯胺酮衍生物及其在精神疾病的治疗中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015501302A (ja) * 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079740A1 (en) * 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015501302A (ja) * 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN. N.Y. ACAD. SCI., vol. Vol. 1345, Issue 1, JPN6021006831, 2015, pages 47 - 58, ISSN: 0004614797 *
BIOL. PSYCHIATRY, vol. Vol. 76, Issue 12, JPN6021006832, 2014, pages 970 - 976, ISSN: 0004614798 *

Also Published As

Publication number Publication date
CN109475514A (zh) 2019-03-15
US20190083420A1 (en) 2019-03-21
CA3019012A1 (en) 2017-09-28
EP3432869A1 (en) 2019-01-30
AU2017238858A1 (en) 2018-10-18
WO2017165877A1 (en) 2017-09-28
WO2017165877A8 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP2019512528A (ja) 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
JP5420534B2 (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
US12558326B2 (en) Method for treating epilepsy
JP6789578B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
EP3310785B1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102931436B1 (ko) 유기 화합물
WO2023081895A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai)
US12606523B2 (en) Deuterated organic compounds and uses thereof
WO2006033318A1 (ja) 環状アミン誘導体又はその塩
WO2023081897A1 (en) Isotopically enriched 3,4-methylenedioxy-n-ethylamphetamine (mde) and stereoisomers thereof
KR20050043776A (ko) 거울상 이성질체로 농축된, 시탈로프람의 데스메틸 및디데스메틸 대사물을 이용한 우울증 및 다른 중추신경계질환 치료방법
US20250091990A1 (en) Deuterated organic compounds and uses thereof
US9463187B2 (en) Methylphenidate derivatives and uses of them
JP2011512414A (ja) 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体
JP2011512414A5 (https=)
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
HK40045266A (en) Method for treating epilepsy
WO2004087124A1 (en) Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
HK1254300B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012